Ovid Therapeutics OVID
2.40
(0.10)
(4.00%)
as of 25 Sep
- Market cap
- $487.3M
- P/E
- 0.0×
Follow OVID
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (25.97%) | (18.77%) | (17.51%) | (60.06%) |
+8 more TTM periods Free account |
|
| (22.30%) | (15.73%) | (14.33%) | (43.64%) | ||
ROIC |
(35.11%) | (54.88%) | (36.33%) | (81.22%) | |
Return on Tangible Assets |
(30.30%) | (16.71%) | (26.25%) | (162.94%) | |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.31) | (0.52) | (0.53) | |
Free Cash Flow |
(54.77) | (41.95) | (38.33) | (37.93) | |
Piotroski F-Score |
4.00 | — | 4.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(16.19%) | (11.48%) | (18.06%) | (45.89%) | |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
427.70% | 0.00% | 352.76% | 377.11% | |
Selling, General and Administrative Expense of Revenue |
335.42% | 0.00% | 332.45% | 341.21% | |
Share Based Compensation of Revenue |
60.87% | 0.00% | 66.29% | 73.71% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.59 | 1.74 | 2.20 | 1.04 | |
Depreciation/Fixed assets |
0.42 | 0.77 | 1.08 | 1.55 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.04 | 0.00 | 0.10 | 0.09 | |
Operating CF per Share |
(0.28) | (0.31) | (0.52) | (0.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
(439.11%) | 0.00% | (240.13%) | (549.64%) |
Columns are period end dates